TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8640969

Group type: EXPERIMENTAL
Intervention: Plasma brain natriuretic peptide (BNP)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Plasma atrial natriuretic peptide (ANP)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: N-terminal proatrial natriuretic peptide (N-ANP)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 131
Study: 1383819

Group type: EXPERIMENTAL
Intervention: CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 325

Group type: COMPARATOR
Intervention: m-BACOD regimen (bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: CHOP regimen
Number of subjects: 325
Study: 4054701

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg tds with meals
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg at bedtime
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg tds with meals plus 400 mg at bedtime
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard regimen (not specified)
Number of subjects: 246
Study: 30114193

Group type: EXPERIMENTAL
Intervention: Seeking care outside the home
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Use of antibiotics
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Medical insurance reimbursement
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Gender influence on care-seeking
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Symptoms influence on antibiotic use
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Type of hospital visited
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Income influence on antibiotic receipt
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Determinants of antibiotic use
Number of subjects: 1103
Study: 26614273

Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 14

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 14
Study: 22988894

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (control group)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Pooled randomized controlled trials (control group)
Number of subjects: 591
Study: 23131886

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110
Study: 21029890

Group type: EXPERIMENTAL
Intervention: Adherent ocular bandage
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 18024487

Group type: COMPARATOR
Intervention: rFSH alone (Gonal-F)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: rFSH + rLH (Luveris)
Number of subjects: 526

Group type: COMPARATOR
Intervention: rFSH alone (Gonal-F) with low LH levels (<33 percentile) on Days 1 and 6
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: rFSH + rLH (Luveris) with low LH levels (<33 percentile) on Days 1 and 6
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: rLH supplementation
Number of subjects: 526
Study: 16369154

Group type: EXPERIMENTAL
Intervention: Objective computerized analysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subjective analysis
Number of subjects: 60
Study: 11834529

Group type: EXPERIMENTAL
Intervention: FCHL-affected subjects
Number of subjects: 46
Study: 10575170

Group type: EXPERIMENTAL
Intervention: IRIV-HAV and YFV
Number of subjects: 105

Group type: COMPARATOR
Intervention: IRIV-HAV
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: YFV
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 7484486

Group type: EXPERIMENTAL
Intervention: Large Cell Ripplebed (AP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventix (CLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Groove prototype (CLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modular Propad (CLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ardo Watersoft (CLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spenco (C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgicgoods Hollowcore Mattress Pad (C)
Number of subjects: 0
Study: 1963130

Group type: EXPERIMENTAL
Intervention: Rate of patient enrollment in the Macular Photocoagulation Study (MPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate of patient enrollment in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactive patients in the Macular Photocoagulation Study (MPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactive patients in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Number of subjects: 0
Study: 7015220

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31217176

Group type: EXPERIMENTAL
Intervention: Baseline levels of oxidized LDL (oxLDL) in circulating immune complexes (LDL‐ICs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline levels of MDA‐modified LDL (MDA‐LDL) in circulating immune complexes (LDL‐ICs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline levels of oxLDL‐IC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline levels of modified LDL‐IC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline levels of modified LDL biomarkers
Number of subjects: 0
Study: 27650328

Group type: EXPERIMENTAL
Intervention: Montelukast (20 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 26807640

Group type: EXPERIMENTAL
Intervention: DC-LOP (IV paclitaxel at 60 mg/m² followed by IV carboplatin at AUC 6 and IV pegylated liposomal doxorubicin at 30 mg/m²)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GC-LOP (IV paclitaxel at 60 mg/m² followed by IV gemcitabine at 1000 mg/m²)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DC-LOP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GC-LOP
Number of subjects: 22
Study: 24625922

Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Indomethacin for 3 days (group 2)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Indomethacin for 1 week (group 3)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Indomethacin for 6 weeks (group 4)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nonunion patients
Number of subjects: 98
Study: 21142292

Group type: EXPERIMENTAL
Intervention: Intravenous microdose of verapamil [0.05 mg] (period 1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous microdose of verapamil [0.05 mg] administered concomitantly with an oral therapeutic dose [80 mg] (period 2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: (R)‐enantiomer of verapamil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: (S)‐enantiomer of verapamil
Number of subjects: 6
Study: 19074961

Group type: EXPERIMENTAL
Intervention: Repeated dose of antenatal betamethasone
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Fetal growth (weight, length, head circumference)
Number of subjects: 142
Study: 16773465

Group type: EXPERIMENTAL
Intervention: Amino acid mixture (108 g) given orally to cirrhotics
Number of subjects: 29
Study: 15222892

Group type: EXPERIMENTAL
Intervention: Rizatriptan (RI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rizatriptan plus rofecoxib (RI + RO)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rizatriptan plus tolfenamic acid (RI + TA)
Number of subjects: 45
Study: 11181660

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (5 years of tamoxifen, polychemotherapy including cyclophosphamide/methotrexate/fluorouracil-like regimens, anthracycline-based therapy, or therapy based on both an anthracycline and a taxane)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant! computer program
Number of subjects: 0
Study: 9393392

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study: 7951404

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate 800 micrograms per day
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Danazol 800 micrograms per day
Number of subjects: 213
Study: 3310669

Group type: EXPERIMENTAL
Intervention: 2 hours of early morning phototherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: 2 hours of early afternoon phototherapy
Number of subjects: 16
Study: 29614502

Group type: EXPERIMENTAL
Intervention: 5% NaF varnish
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5% NaF + tricalcium phosphate (TCP) varnish
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5% NaF + amorphous calcium phosphate (ACP) varnish
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27225722

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine, 1 g/L for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study: 25140957

Group type: EXPERIMENTAL
Intervention: GS-5806 (50 mg first dose, then 25 mg daily for 4 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23768274

Group type: EXPERIMENTAL
Intervention: Alfredson's exercise programme
Number of subjects: 41

Group type: COMPARATOR
Intervention: Stanish's exercise programme
Number of subjects: 41
Study: 21733370

Group type: EXPERIMENTAL
Intervention: estradiol and drospirenone tablets (Angeliq)
Number of subjects: 244

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 244
Study: 18494340

Group type: EXPERIMENTAL
Intervention: wavefront-optimized LASIK
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: customized LASIK
Number of subjects: 100
Study: 16473758

Group type: EXPERIMENTAL
Intervention: Acupuncture and herbal medicine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Promotion of trials to the wider community
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Trial acceptability
Number of subjects: 5
Study: 12571165

Group type: EXPERIMENTAL
Intervention: Metformin for 6 months followed by clomiphene citrate
Number of subjects: 60

Group type: COMPARATOR
Intervention: hMG for ovulation induction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cost-effective analysis for medications per pregnancy in group I
Number of subjects: 60
Study: 10920060

Group type: EXPERIMENTAL
Intervention: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among nondiabetic men
Number of subjects: 87938

Group type: EXPERIMENTAL
Intervention: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among diabetic men
Number of subjects: 87938
Study: 8751736

Group type: EXPERIMENTAL
Intervention: Embryos grown in groups (study group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Embryos grown individually (control group)
Number of subjects: 91
Study: 1566986

Group type: EXPERIMENTAL
Intervention: Intravenous tubocurarine 0.05 mg.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous chlorpromazine 0.1 mg.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alphatocopherol (vitamin E) 600 mg in three divided doses orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous calcium chloride 5 mg.kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 120
Study: 3905182

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30986285

Group type: EXPERIMENTAL
Intervention: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 1, n = 24)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 2, n = 23)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional two-dimensional radiograph and free-hand implant placement (control, n = 26)
Number of subjects: 73
Study: 28855085

Group type: EXPERIMENTAL
Intervention: Waist accelerometer (ActiGraph GT3X+), pedometer-assessed step counts (Yamax SW-200, 7 days)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Wrist accelerometer (ActiGraph GT3X+), pedometer-assessed step counts
Number of subjects: 366

Group type: COMPARATOR
Intervention: Wrist group participants
Number of subjects: 366
Study: 26864301

Group type: EXPERIMENTAL
Intervention: Combination treatment of fractional 1550-nm ytterbium/erbium fiber laser and 0.1% tacrolimus ointment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 120
Study: 22907761

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 4208

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 4208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4208
Study: 20123821

Group type: EXPERIMENTAL
Intervention: Collaborative care for depression
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Multiple assessments (baseline, three months, six months, and 12 months)
Number of subjects: 906
Study: 17544560

Group type: EXPERIMENTAL
Intervention: elmex Sensitive Extra Soft (ESES)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: elmex Sensitive Soft (ESS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: ADA standard toothbrush (ADAS)
Number of subjects: 84
Study: 15213039

Group type: COMPARATOR
Intervention: Lutein supplement in oil (LS treatment, 1.7 mg lutein/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Yellow carrots (YC treatment, 1.7 mg lutein/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: White carrots (WC treatment, 0 mg lutein/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Yellow carrots (YC treatment)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lutein supplement in oil (LS treatment)
Number of subjects: 9
Study: 11448369

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Venlafaxine hydrochloride (37.5 mg twice-daily)
Number of subjects: 28
Study: 9539918

Group type: EXPERIMENTAL
Intervention: Griseofulvin (10 mg/kg/day for 8 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Terbinafine (62.5‐250 mg/day for 4 weeks)
Number of subjects: 24
Study: 8024798

Group type: EXPERIMENTAL
Intervention: Topical all-trans retinoic acid gel (Aberel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salicylic acid gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 0
Study: 2478341

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA), 5 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Previous study with 50 mg/day CMA
Number of subjects: 12
Study: 7375

Group type: EXPERIMENTAL
Intervention: bromazepam (9 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: diazepam (10 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 29947134

Group type: EXPERIMENTAL
Intervention: Bakuchiol 0.5% cream applied twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Retinol 0.5% cream applied daily
Number of subjects: 44
Study: 28327054

Group type: EXPERIMENTAL
Intervention: Low frequency (LF) rTMS + physical therapy (PT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low frequency (LF) rTMS + NMES + physical therapy (PT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physical therapy (PT) only
Number of subjects: 25
Study: 26126419

Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT) weekly for 9 months; monthly thereafter
Number of subjects: 120

Group type: COMPARATOR
Intervention: Generic environmental supports
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT)
Number of subjects: 120
Study: 23535290

Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (high scores for total integration)
Number of subjects: 9252

Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (ART integration)
Number of subjects: 9252

Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (internal integration)
Number of subjects: 9252

Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (total integration)
Number of subjects: 9252

Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (pre-ART integration)
Number of subjects: 9252

Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (mainstreaming HIV)
Number of subjects: 9252
Study: 22013172

Group type: EXPERIMENTAL
Intervention: I-125 brachytherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0
Study: 19179111

Group type: EXPERIMENTAL
Intervention: Annual follow-up visits by a specialist nurse
Number of subjects: 200

Group type: COMPARATOR
Intervention: Physician-led visits including oximetry
Number of subjects: 200
Study: 16507179

Group type: EXPERIMENTAL
Intervention: Midazolam (administered in small, divided doses over 4-5 min until Wilson sedation score reached three)
Number of subjects: 38
Study: 16254093

Group type: EXPERIMENTAL
Intervention: Performance-approach goal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mastery goal (standard)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated mastery goal (more difficult)
Number of subjects: 0
Study: 12173139

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (3 mg retinol equivalent)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Control (iron and folate alone)
Number of subjects: 697
Study: 9949754

Group type: EXPERIMENTAL
Intervention: Intervention group (cessation intervention)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 7582385

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg (0.32 +/- 0.07 mg.kg‐1) as a 10 mg.ml‐1 solution
Number of subjects: 8
Study: 2316832

Group type: EXPERIMENTAL
Intervention: Fentanyl 7 micrograms/kg via a central venous catheter
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fentanyl 7 micrograms/kg through a peripheral venous cannula
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sterile water via a central venous catheter
Number of subjects: 110
Study: 350498

Group type: EXPERIMENTAL
Intervention: Methylcysteine hydrochloride (1200 mg daily in Week 1, 800 mg daily in Week 2, then 600 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (identical tablets, same regimen)
Number of subjects: 30
Study: 31001695

Group type: EXPERIMENTAL
Intervention: Cancer survivors (5 years after diagnosis)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Cancer survivors (10 years after diagnosis)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Cancer survivors younger than 60 years
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Women cancer survivors
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Elderly cancer survivors
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Financial problems, global quality of life, cognitive function
Number of subjects: 1002
Study: 30893645

Group type: EXPERIMENTAL
Intervention: HMUFA diet
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: HSFA diet
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: LFHCC n‐3
Number of subjects: 486

Group type: COMPARATOR
Intervention: LFHCC control
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: High-fat diets (HSFA and HMUFA)
Number of subjects: 486
Study: 28629872

Group type: EXPERIMENTAL
Intervention: Sevoflurane administered at 1 minimal alveolar concentration for 5 minutes after being weaned from CPB (group SEV)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Intravenous anesthesia maintained (group CTRL)
Number of subjects: 190
Study: 26403536

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 1004
Study: 23412700

Group type: EXPERIMENTAL
Intervention: Camostat (1.6 mg dose group)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Camostat (estimated dose of 18 μg/mL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Camostat and Placebo
Number of subjects: 9
Study: 21948536

Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis procedure (n=116)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Sweet procedure (n=116)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis procedure
Number of subjects: 232

Group type: COMPARATOR
Intervention: Sweet procedure
Number of subjects: 232
Study: 19445719

Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AWS laryngoscope
Number of subjects: 25

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study: 17386280

Group type: EXPERIMENTAL
Intervention: Top hat-shaped PKP using a femtosecond laser
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional PKP
Number of subjects: 14
Study: 15359920

Group type: EXPERIMENTAL
Intervention: Water-pipe smokers (WPS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive smokers (PS)
Number of subjects: 25
Study: 11394515

Group type: EXPERIMENTAL
Intervention: 20 microg fentanyl (0.4 ml)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Saline 0.9% (0.4 ml)
Number of subjects: 52
Study: 9972118

Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial-dose doxycycline (SDD) 20 mg BID
Number of subjects: 0
Study: 8071758

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin A supplementation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Enteral vitamin A supplementation
Number of subjects: 51
Study: 3179171

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg every 6 h for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Phenytoin sodium (400 mg single oral dose)
Number of subjects: 8
Study: 5309085

Group type: EXPERIMENTAL
Intervention: Direct BCG vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two different vaccines
Number of subjects: 0